SummaryActivation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTORC1-mediated inhibition of upstream signaling. We now show that AKT inhibition induces the expression and phosphorylation of multiple receptor tyrosine kinases (RTKs). In a wide spectrum of tumor types, inhibition of AKT induces a conserved set of RTKs, including HER3, IGF-1R, and insulin receptor. This is in part due to mTORC1 inhibition and in part secondary to a FOXO-dependent activation of receptor expression. PI3K-AKT inhibitors relieve this feedback and activate RTK signaling; this may attenuate their antitumor activity. Consistent with this model, we find that, in tumors in which AKT suppresses HER3 expression, combined inhibition of A...
Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, ...
Resistance to chemotherapy is a major cause of treatment failure in human cancer. Accumulating evide...
Using a model of medroxyprogesterone acetate (MPA)-induced mouse mammary tumors that transit through...
SummaryActivation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTO...
SummaryThe downstream effector of PI3K, Akt, is frequently hyperactivated in human cancers. A critic...
We explore mechanisms that enable cancer cells to tolerate PI3K or Akt inhibitors. prolonged treatme...
SummaryAkt contributes to tumorigenesis by inhibiting apoptosis. Here we establish that Akt is requi...
We explore mechanisms that enable cancer cells to tolerate PI3K or Akt inhibitors. Prolonged treatme...
SummaryHyperactive PI3K/mTOR signaling is prevalent in human malignancies and its inhibition has pot...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
The ser-thr Akt plays a critical role in the regulation of cell survival, cell growth and proliferat...
Cancer therapeutic resistance; Target identificationResistencia terapéutica contra el cáncer; Identi...
AbstractInhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosp...
While NF-κB is considered to play key roles in the development and progression of many cancers, the ...
Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozo...
Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, ...
Resistance to chemotherapy is a major cause of treatment failure in human cancer. Accumulating evide...
Using a model of medroxyprogesterone acetate (MPA)-induced mouse mammary tumors that transit through...
SummaryActivation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTO...
SummaryThe downstream effector of PI3K, Akt, is frequently hyperactivated in human cancers. A critic...
We explore mechanisms that enable cancer cells to tolerate PI3K or Akt inhibitors. prolonged treatme...
SummaryAkt contributes to tumorigenesis by inhibiting apoptosis. Here we establish that Akt is requi...
We explore mechanisms that enable cancer cells to tolerate PI3K or Akt inhibitors. Prolonged treatme...
SummaryHyperactive PI3K/mTOR signaling is prevalent in human malignancies and its inhibition has pot...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
The ser-thr Akt plays a critical role in the regulation of cell survival, cell growth and proliferat...
Cancer therapeutic resistance; Target identificationResistencia terapéutica contra el cáncer; Identi...
AbstractInhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosp...
While NF-κB is considered to play key roles in the development and progression of many cancers, the ...
Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozo...
Dysregulated PI3K/Akt signaling occurs commonly in breast cancers and is due to HER2 amplification, ...
Resistance to chemotherapy is a major cause of treatment failure in human cancer. Accumulating evide...
Using a model of medroxyprogesterone acetate (MPA)-induced mouse mammary tumors that transit through...